BIOGEN INC. Disposal Group, Not Discontinued Operation, Loss (Gain) on Write-down
BIOGEN INC. (BIIB) reported Disposal Group, Not Discontinued Operation, Loss (Gain) on Write-down of $0 for the 12-month period ending 2022-12-31, per its 10-K filed 2023-02-15.
Discontinued › Expense Statement › Operating Expenses
us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown · last filed 2023-02-15
- BIOGEN INC. disposal group, not discontinued operation, loss (gain) on write-down for the quarter ending 2020-12-31 was -$92.50M.
- BIOGEN INC. disposal group, not discontinued operation, loss (gain) on write-down for the quarter ending 2020-09-30 was $0.00.
- BIOGEN INC. disposal group, not discontinued operation, loss (gain) on write-down for the quarter ending 2020-06-30 was $0.00.
- BIOGEN INC. disposal group, not discontinued operation, loss (gain) on write-down for the quarter ending 2020-03-31 was $0.00, a 100.00% decline year-over-year.
- BIOGEN INC. disposal group, not discontinued operation, loss (gain) on write-down for fiscal 2022 was $0.00.
- BIOGEN INC. disposal group, not discontinued operation, loss (gain) on write-down for fiscal 2021 was $0.00.
- BIOGEN INC. disposal group, not discontinued operation, loss (gain) on write-down for fiscal 2020 was -$92.50M, a 267.27% decline from fiscal 2019.
- BIOGEN INC. disposal group, not discontinued operation, loss (gain) on write-down for fiscal 2019 was $55.30M.
| Period end | Disposal Group, Not Discontinued Operation, Loss (Gain) on Write-down 3 month | Disposal Group, Not Discontinued Operation, Loss (Gain) on Write-down 6 month | Disposal Group, Not Discontinued Operation, Loss (Gain) on Write-down 9 month | Disposal Group, Not Discontinued Operation, Loss (Gain) on Write-down 12 month |
|---|---|---|---|---|
| 2022-12-31 | $0.00 10-K · filed 2023-02-15 | |||
| 2021-12-31 | $0.00 10-K · filed 2023-02-15 | |||
| 2020-12-31 | -$92.50M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-15 | -$92.50M derived: sum of 2 quarters · filed 2023-02-15 | -$92.50M derived: sum of 3 quarters · filed 2023-02-15 | -$92.50M 10-K · filed 2023-02-15 |
| 2020-09-30 | $0.00 10-Q · filed 2020-10-21 | $0.00 derived: sum of 2 quarters · filed 2020-10-21 | $0.00 10-Q · filed 2020-10-21 | -$40.20M derived: sum of 4 quarters · filed 2022-02-03 |
| 2020-06-30 | $0.00 10-Q · filed 2020-07-22 | $0.00 10-Q · filed 2020-07-22 | -$40.20M derived: sum of 3 quarters · filed 2022-02-03 | -$57.90M derived: sum of 4 quarters · filed 2022-02-03 |
| 2020-03-31 | $0.00 10-Q · filed 2020-04-23 | -$40.20M derived: sum of 2 quarters · filed 2022-02-03 | -$57.90M derived: sum of 3 quarters · filed 2022-02-03 | -$60.20M derived: sum of 4 quarters · filed 2022-02-03 |
| 2019-12-31 | -$40.20M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-03 | -$57.90M derived: sum of 2 quarters · filed 2022-02-03 | -$60.20M derived: sum of 3 quarters · filed 2022-02-03 | $55.30M 10-K · filed 2022-02-03 |
| 2019-09-30 | -$17.70M 10-Q · filed 2019-10-22 | -$20.00M derived: sum of 2 quarters · filed 2019-10-22 | $95.50M 10-Q · filed 2020-10-21 | $95.50M derived: sum of 4 quarters · filed 2021-02-03 |
| 2019-06-30 | -$2.30M 10-Q · filed 2019-07-24 | $113.20M 10-Q · filed 2020-07-22 | $113.20M derived: sum of 3 quarters · filed 2021-02-03 | $113.20M derived: sum of 4 quarters · filed 2021-02-03 |
| 2019-03-31 | $115.50M 10-Q · filed 2019-04-24 | $115.50M derived: sum of 2 quarters · filed 2021-02-03 | $115.50M derived: sum of 3 quarters · filed 2021-02-03 | $115.50M derived: sum of 4 quarters · filed 2021-02-03 |
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-03 | $0.00 derived: sum of 2 quarters · filed 2021-02-03 | $0.00 derived: sum of 3 quarters · filed 2021-02-03 | $0.00 10-K · filed 2021-02-03 |
| 2018-09-30 | $0.00 10-Q · filed 2019-10-22 | $0.00 derived: sum of 2 quarters · filed 2019-10-22 | $0.00 10-Q · filed 2019-10-22 | |
| 2018-06-30 | $0.00 10-Q · filed 2019-07-24 | $0.00 10-Q · filed 2019-07-24 | ||
| 2018-03-31 | $0.00 10-Q · filed 2019-04-24 | |||
| 2017-12-31 | $0.00 10-K · filed 2020-02-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |